|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
EP0584266B1
(en)
|
1991-05-06 |
2003-09-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
WO1996009380A1
(en)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Method of enhancing expression of mhc class i molecules bearing endogenous peptides
|
|
DE69519521T2
(de)
|
1994-10-03 |
2001-06-28 |
The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
PT939804E
(pt)
|
1996-10-25 |
2005-11-30 |
Human Genome Sciences Inc |
Neutroquina alfa
|
|
ATE299938T1
(de)
|
1997-05-02 |
2005-08-15 |
Genentech Inc |
Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
US6375952B1
(en)
|
1998-08-07 |
2002-04-23 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
|
US7833529B1
(en)
*
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
SI1642972T1
(sl)
|
1999-01-07 |
2010-05-31 |
Zymogenetics Inc |
Terapevtske uporabe BR X topnih receptorjev
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US20030022233A1
(en)
|
1999-04-30 |
2003-01-30 |
Raymond G. Goodwin |
Methods of use of the taci/taci-l interaction
|
|
CA2379166C
(en)
|
1999-08-09 |
2013-03-26 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
|
|
BRPI0209933B8
(pt)
|
2001-05-24 |
2021-05-25 |
Zymogenetics Inc |
proteína de fusão, e, molécula de ácido nucleico
|
|
DE60235041D1
(de)
|
2001-11-30 |
2010-02-25 |
Us Gov Health & Human Serv |
Und ihre verwendung
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
EP1810979B1
(en)
|
2004-09-22 |
2012-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG4 ANTIBODIES
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
BRPI0711823A2
(pt)
*
|
2006-05-15 |
2012-01-17 |
Ares Trading Sa |
métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
US20090186040A1
(en)
*
|
2007-06-13 |
2009-07-23 |
Busby Sharon J |
DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT
|
|
CN101323643B
(zh)
|
2007-06-15 |
2010-12-01 |
烟台荣昌生物工程有限公司 |
优化的TACI-Fc融合蛋白
|
|
PL2222861T3
(pl)
|
2007-12-11 |
2018-04-30 |
The University Of North Carolina At Chapel Hill |
Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym
|
|
JP6017317B2
(ja)
*
|
2011-02-02 |
2016-10-26 |
第一三共株式会社 |
ペプチド・ライブラリー
|
|
EP2686345B1
(en)
|
2011-03-16 |
2018-04-25 |
Amgen Inc. |
Fc variants
|
|
EA027236B1
(ru)
|
2011-04-08 |
2017-07-31 |
Иммьюн Дизайн Корп. |
Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
|
|
JP6355563B2
(ja)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Ｘｔｅｎ共役組成物およびそれを製造する方法
|
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
US10562954B2
(en)
*
|
2014-05-12 |
2020-02-18 |
Shanghai Kanda Biotechnology Co., Ltd. |
Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
|
|
KR20170032373A
(ko)
|
2014-07-15 |
2017-03-22 |
이뮨 디자인 코포레이션 |
Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
FI3380522T3
(fi)
|
2015-11-25 |
2024-01-16 |
Visterra Inc |
Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
|
|
EP4146684A2
(en)
*
|
2020-05-08 |
2023-03-15 |
Alpine Immune Sciences, Inc. |
April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
|